EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Has the consistency evaluation policy of generic drugs promoted the innovation quality of Chinese pharmaceutical manufacturing industry? An empirical study based on the difference-in-differences model

Qiang Liu, Zhe Huang, Zhenbin Mao

Frontiers in Public Health · 01.12.2023 · 11

DOI: 10.3389/fpubh.2023.1265756 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 01.12.2023. Verfasst von Qiang Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China. Hauptthemen laut MEDLINE: Drugs, Generic, Inventions. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In March 2016, the Chinese government officially launched a nationwide consistency evaluation of the quality and efficacy of generic drugs.

Methods

This paper conducted an empirical study using the Difference-in-Differences method to explore the effect of this policy on the innovation quality of China’s pharmaceutical manufacturing industry and further analyzed the underlying mechanism of action.

Results

The results of the study show that the generic consistency evaluation policy has a significant promotion effect on the innovation quality of China’s pharmaceutical manufacturing industry, and the promotion effect is the largest for non-state-owned enterprises and enterprises in the central region; in addition, the intensity of R&D capital investment and R&D personnel investment which play a mediating role.

Discussion

Therefore, we should fully recognize the positive effect of generic drug consistency evaluation policy on improving the innovation quality of the pharmaceutical manufacturing industry and pay attention to the necessity of regional coordination and unification in policy implementation and the formulation of supporting policy tools. This study provides empirical evidence for the implementation effect of the generic drug consistency evaluation policy, which can provide an essential reference for the further improvement of the procedure and the R&D decision-making of pharmaceutical enterprises.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, GenericInventionsManufacturing IndustryDrug IndustryPublic PolicyChina

Stichwörter der Autor:innen

consistent evaluation policy of generic drugsdifference-in-differences modelinnovation qualitymediating effectpharmaceutical manufacturing industry

Substanzen

Drugs, Generic

Autor:innen und Institutionen

  • School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China.
  • Research Institute of Drug Regulatory Science, Shenyang Pharmaceutical University, Shenyang, China.

Zitieren

APA

Liu, Q., Huang, Z., & Mao, Z. (2023). Has the consistency evaluation policy of generic drugs promoted the innovation quality of Chinese pharmaceutical manufacturing industry? An empirical study based on the difference-in-differences model. Frontiers in Public Health, 11. https://doi.org/10.3389/fpubh.2023.1265756

Vancouver

Liu Q, Huang Z, Mao Z. Has the consistency evaluation policy of generic drugs promoted the innovation quality of Chinese pharmaceutical manufacturing industry? An empirical study based on the difference-in-differences model. Frontiers in Public Health. 2023;11. doi:10.3389/fpubh.2023.1265756

BibTeX
@article{Liu2023,
  author = {Liu, Qiang and Huang, Zhe and Mao, Zhenbin},
  title = {Has the consistency evaluation policy of generic drugs promoted the innovation quality of Chinese pharmaceutical manufacturing industry? An empirical study based on the difference-in-differences model},
  journal = {Frontiers in Public Health},
  year = {2023},
  volume = {11},
  doi = {10.3389/fpubh.2023.1265756}
}
Kostenlos starten →